Dr. John M. Timmerman, MD

Expert Publications

• Dendritic cell vaccines for cancer immunotherapy.
• Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
• The history of the development of vaccines for the treatment of lymphoma.
• BLyS and BLyS receptor expression in non-Hodgkin's lymphoma.
• Vaccine therapies for non-Hodgkin's lymphoma.
• Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
• Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.
• Immunotherapy for lymphomas.
• Extending the utility of gene profiling data by bridging microarray platforms.
• Therapeutic idiotype vaccines for non-Hodgkin's lymphoma.
• Cancer vaccines: pessimism in check.
• Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
• Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
• Vaccine therapies for non-Hodgkin's lymphomas.
• Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.

Media Releases

Get to know Immunologist and Hematologist-Oncologist, Dr. John M. Timmerman, MD, who serves patients in Santa Monica, California.

Dr. Timmerman is a board certified hematologist-oncologist currently practicing at Santa Monica Cancer Care at UCLA Health in Santa Monica, California. Academically, he maintains a position as Associate Professor of Medicine in the UCLA Lymphoma Program, which is part of the Division of Hematology & Oncology in the Department of Medicine at UCLA. Dr. Timmerman is also a member of the Tumor Immunology Program within the UCLA Jonsson Comprehensive Cancer Center and the UCLA Molecular Biology Institute.

Dr. Timmerman earned his medicaid degree in 1991 at the prestigious Boston University School of Medicine in Boston, MAssachusetts. He then served his internship (1991-1992) and internal medicine residency (1992-1994) at the University of California San Francisco School of Medicine in San Francisco, California. In 1998, he completed his fellowship in hematology-oncology at Stanford University School of Medicine in Stanford, California. Prior to medical school, Dr. Timmerman received his undergraduate degrees in biochemistry and physiology from the University of California, Berkeley, and his Master’s degree from Boston University.

Following his training, Dr. Timmerman attained board certification in internal medicine, medical oncology, and hematology through the American Board of Internal Medicine (ABIM). The American Board of Internal Medicine is a 501 nonprofit, self-appointed physician-evaluation organization that certifies physicians practicing internal medicine and its subspecialties. The American Board of Internal Medicine is not a membership society, educational institution, or licensing body.

Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. It involves treating diseases that affect the production of blood and its components, such as blood cells, hemoglobin, blood proteins, bone marrow, platelets, blood vessels, spleen, and the mechanism of coagulation. Such diseases might include hemophilia, blood clots (thrombus), other bleeding disorders, and blood cancers such as leukemia, multiple myeloma, and lymphoma.

Oncology is the study of cancer. The field of oncology has three major areas: medical, surgical, and radiation. A medical oncologist treats cancer using chemotherapy or other medications, such as targeted therapy or immunotherapy. A surgical oncologist removes the tumor and nearby tissue during surgery. A radiation oncologist treats cancer using radiation therapy.

Licensed to practice in California, Dr. Timmerman maintains hospital privileges at Ronald Reagan UCLA Medical Center Los Angeles, California, and UCLA Santa Monica Medical Center in Santa Monica, California. Included in Southern California Super Doctors® (2010-2012), he is actively involved in research with a special interest in the treatment of non-Hodgkin and Hodgkin lymphomas, tumor immunology, and immunotherapy of lymphomas. 

Recommended Articles

• Breaking News on the Treatment of Follicular Lymphoma

  Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...

• Morphos Declared a "Breakthrough Therapy" for Lymphoma

  MorphoSys’s main objective is to design exceptional and unique biopharmaceuticals, all designed to enhance the lives of patients suffering from severe or life-threatening conditions.The human body has two types of lymphocytes that can develop into lymphomas: B lymphocytes (B cells) and T...

• Lymphoma News: Mother Gives Birth to Healthy Daughter after Chemo During Pregnancy

  Chemotherapy has a reputation for its not-so-great side effects. As many people know, chemotherapy is known to cause off target symptoms for most cancer patients such as nausea and vomiting, hair loss, and extreme fatigue. In addition to the symptoms that one may experience during treatment, some of...

• Roles of the National Coalition for Cancer Survivorship

  The National Coalition for Cancer Survivorship (NCCS) is a nonprofit, cancer advocacy organization that is located just outside of Washington D.C. To date, it is the oldest survivor-led cancer advocacy organization in the United States.The NCCS represents millions of Americans who share a common...

• Living as a Hodgkin Lymphoma Survivor: Creating a New Normal

  No one can ever truly be prepared for what it is like to live with cancer. Even the strongest survivors face setbacks, and some of the fiercest warriors share their stories of how they find their "new normals."Kimberly's storyWhen she was only 25, just five days before her wedding, Kimberly felt a...

• The Promising Future of Gene Therapy and Lymphoma

  Non-Hodgkin lymphoma affects over 700,000 people in America alone. Though current treatments are moderately effective, especially for aggressive forms of the disease, more can be done to help people impacted by NHL. Researchers are doing just that by working to develop new, innovative treatment for...